MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2022 International Congress

    Awake Bruxism, a case series of an underrecognized disorder

    I. Trigo, B. Solano Vila, D. Domínguez (Girona, Spain)

    Objective: We present a series of 3 cases with Awake Bruxism (AB) and frontal dysfunction. Background: AB is an infrequent, daytime form of bruxism, described…
  • 2022 International Congress

    Pseudodystonia due to Palmaris Brevis Syndrome: Case Report

    D-Y. Liou, A. Alamoudi, D. Preston, C. Kilbane (Cleveland, USA)

    Objective: We describe a case of pseudodystonia caused by palmaris brevis syndrome. Background: Palmaris brevis (PB) syndrome is a pseudodystonia characterized by spontaneous, involuntary, nonpainful…
  • 2022 International Congress

    Botulinum Toxin Outcomes in Patients with Lower Limb Dystonia

    M. Wajid, J. Frey, L. Kugler, T. Stiep, J. Yu, J. Toledo, J. Lopes, A. Ramirez-Zamora, A. Rawls, A. Wagle Shukla, I. Malaty (Gainesville, USA)

    Objective: To assess botulinum toxin outcomes in patients with lower limb dystonia. Background: One of the most effective treatments for dystonia is botulinum toxin (BoNT)…
  • 2022 International Congress

    Development of a patient journey map for people living with cervical dystonia

    M. Benson, A. Albanese, K. Bhatia, P. Cavillon, L. Cuffe, K. König, C. Reinhard, H. Graessner (Brussels, Belgium)

    Objective: As part of the ongoing European Reference Networks for Rare Neurological Diseases (ERN-RND) program, we aimed to develop a cervical dystonia patient journey map…
  • 2022 International Congress

    A bitter syndrome as a cause of refractory movement disorders

    DD. García-Meléndez, F. Muñoz Escudero, MI. Morales-Casado, P. Lobato Casado, AM. Diezma Martín, G. Tabar Comellas, N. Sánchez Cano, B. Canovas Gaillemin, N. López Ariztegui (Toledo, Spain)

    Objective: Submit a case of GLUT-1 deficiency for consideration in the differential diagnosis of movement disorders and refractory epilepsies because early treatment will prevent progressive…
  • 2022 International Congress

    Treatment of upper limb dystonic tremors: a retrospective study

    B. Gonzalez-Herrero, I. Di Vico, M. Edwards, F. Morgante (London, United Kingdom)

    Objective: Our study aimed to evaluate the clinical outcome of patients with upper-limb dystonic tremor (UL-DTs) treated at a tertiary hospital in London. Background: Tremor…
  • 2022 International Congress

    Impact of botulinum toxin treatment on gait in focal dystonia

    J. Cuinat, B. Debu, P. Pelissier, A. Castrioto, S. Meoni, S. Potel, V. Fraix, E. Moro (Grenoble, France)

    Objective: To study the effects of botulinum neurotoxin (BTX) treatment on gait characteristics in patients with blepharospasm and cervical dystonia. Background: The impact of focal…
  • 2022 International Congress

    Changes in botulinum toxin dosing in cervical dystonia over 7 years

    S. Rafee, M. Hutchinson (Dublin, Ireland)

    Objective: To assess changes in botulinum toxin dosing over the course of illness of cervical dystonia. Background: Muscle specific botulinum toxin injections remains the main…
  • 2022 International Congress

    Use of bupivacaine in the evaluation of acute secondary cervical dystonia (CD)

    JR. Chai, S. Bansal, C. Li, M. Jog (London, Canada)

    Objective: To highlight the potential use of bupivacaine/analgesics in assessing cervical dystonia, where disabling local pain can be a confounder and limits clinical examination. Background:…
  • 2022 International Congress

    Botulinum Toxin Therapy for Medication and DBS Refractory Foot Dystonia of Parkinsonism

    E. Zinoviev, M. Ganapathy, M. Siddiqui (Winston-Salem, USA)

    Objective: To determine efficacy and safety of BTX therapy in patients with medically refractory foot dystonia secondary to Parkinson’s disease (PD) or atypical Parkinsonism (AP)…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley